Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities
2011

GLP-1, Diabetes, and Cognitive Decline

publication Evidence: moderate

Author Information

Author(s): Mossello Enrico, Ballini Elena, Boncinelli Marta, Monami Matteo, Lonetto Giuseppe, Mello Anna Maria, Tarantini Francesca, Baldasseroni Samuele, Mannucci Edoardo, Marchionni Niccolò

Primary Institution: University of Florence and Careggi Teaching Hospital

Hypothesis

The study investigates the potential link between glucagon-like peptide-1 (GLP-1) dysfunction and cognitive decline in Type 2 diabetes mellitus (T2DM).

Conclusion

The study suggests that GLP-1 dysfunction may mediate the relationship between T2DM and cognitive decline, indicating potential therapeutic opportunities.

Supporting Evidence

  • GLP-1 levels are reduced in Type 2 diabetes, which may affect brain health.
  • Studies suggest that GLP-1 may have neuroprotective effects against Alzheimer's disease.
  • GLP-1 analogues have shown promise in enhancing cognitive function in animal models.

Takeaway

This study looks at how a hormone called GLP-1, which helps control blood sugar, might also protect our brain from problems like Alzheimer's disease, especially in people with diabetes.

Methodology

The study reviews experimental research linking GLP-1 dysfunction to cognitive decline in T2DM.

Digital Object Identifier (DOI)

10.1155/2011/281674

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication